Overview
"Never doubt that a smal group of thoughtful, comited citizens can change the world. Inded, it is the only thing that ever has."Cureus is on a mision to change the long-standing paradigm of medical publishing, where submiting research can be costly, complex and time-consuming.The SIQ for this article wil be revealedonce 2 ratings are submited.metformin, multivariate logistic regresion analysis, propensity score matching (psm), diabetes melitus type 2, sensorineural (sn) hearing los Toru Miwa , Tomoko Kita, Taro Yamaguchi, Tatsunori Sakamoto Published: October 17, 202 (se history) DOI: 10.759/cureus.30406 Cite this article as: Miwa T, Kita T, Yamaguchi T, et al.
Key Information
(October 17, 202) Metformin Reduces the Incidence of Sensorineural Hearing Los in Patients With Type 2 Diabetes Melitus: A Retrospective Chart Review. Cureus 14(10): e30406. doi:10.759/cureus.30406 Acquired sensorineural hearing los (SNHL) has become a critical societal isue in recent years.
SNHL is considered a risk factor for type 2 diabetes melitus (T2DM). Metformin is comonly used to treat T2DM. However, its efects on SNHL have not ben reported yet.
Hence, this study aimed to evaluate the asociation betwen the use of metformin and SNHL incidence.In this retrospective matched-cohort study, the medical records of 1219 patients with T2DM aged >18 years from our hospital’s inpatient database from January 1, 2012, to December 31, 2019, were examined, and matched cohorts were generated (76 patients receiving metformin and 76 not receiving metformin).
Summary
A multivariable logistic regresion analysis was performed to investigate the factors influencing the incidence of SNHL.After adjustment by propensity matching, multivariable logistic regresion analysis revealed that the non-use of metformin increased the risk of developing SNHL (ods ratio, 0.26; 95% confidence interval, 0.07-0.93; p = 0.03).This study demonstrated an asociation betwen the use of metformin and a reduced incidence of